Dr. Alan Brown is joined by Dr. Thomas Dayspring, Director of Cardiovascular Education for the Foundation for Health Improvement and Technology in Richmond, VA and clinical assistant professor of medicine at the UMDNJ - NJ Medical School. He is also a Fellow of both the American College of Physicians and the National Lipid Association. The two discuss Dr. Dayspring's research on discordances between LDL-P and ApoB, two biomarkers that are otherwise thought to correlate well with one another.
Lipid Biomarker Updates: When to Move Beyond the Standard Profile
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Dr. Alan Brown is joined by Dr. Thomas Dayspring, Director of Cardiovascular Education for the Foundation for Health Improvement and Technology in Richmond, VA and clinical assistant professor of medicine at the UMDNJ - NJ Medical School. He is also a Fellow of both the American College of Physicians and the National Lipid Association. The two discuss Dr. Dayspring's research on discordances between LDL-P and ApoB, two biomarkers that are otherwise thought to correlate well with one another.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Evolving Our View of the Coagulation Cascade and Stroke Management
0.25 credits
<p><span data-contrast="auto" xml:lang="EN-US">Evolving Our View of the Coagulation Cascade and Stroke Management</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
Perspectives with the AMA
Implementing the AMA MAPTM Hypertension Program: A Clinician’s Experience
<p>Implementing the AMA MAP™ Hypertension Program: A Clinician's Experience</p>
MinuteCE®
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
1.25 credits
<p>Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer</p>
MinuteCE®
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
1.00 credits
<p>Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 credits
<p>Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?